Download
1 / 7
70 likes | 219 Views
National Management of Hospital Pharmaceuticals and Medical Devices . Andrew Davies Acting Manager, Funding & Procurement. Background. Ministerial Review Group advocated improved prioritisation in health funding decisions Different levels of access across country
E N D
National Management of Hospital Pharmaceuticals and Medical Devices Andrew Davies Acting Manager, Funding & Procurement
Background • Ministerial Review Group advocated improved prioritisation in health funding decisions • Different levels of access across country • There is limited resource, and choices need to be made • Cabinet asked PHARMAC to: • expand its role to include all hospital pharmaceuticals • work with MoH and others to develop a national plan for medical devices
Hospital Pharmaceuticals Subcommittee Hospital Pharmaceuticals Subcommittee SpecialistSubcommittee DHB Hospitals Colleges Consultation with wider sector PTAC Hospital Medicines
Medical Devices • Number of challenges • No baseline • Clinical advice structures? • Health Benefits Limited working with District Health Boards to develop national data collection • PHARMAC looking at insulin pumps as a test case
Summary • PHARMAC is developing a national list of hospital medicines • Evidence based • Clinical input important • Aims to improve consistency of access across DHBs • Medical Devices • Understanding where we are now is critical • Information systems being improved • National plan later this year
Table Discussion • How can you manage the tension between clinical/patient choice and value for money when funding is limited? • Do you think this is different for hospital pharmaceuticals and medical devices, and why?
